{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:55:21Z","timestamp":1793328921202,"version":"4.5.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>One of the major challenges for all imaging modalities is accurate detection of prostate cancer (PCa) recurrence. Beyond the established <jats:sup>68<\/jats:sup>Ga-PSMA, a novel promising PET tracer in PCa imaging is <jats:sup>18<\/jats:sup>F-fluciclovine. For evaluating the advantages and disadvantages and the comparability, we conducted a prospective head-to-head comparison on <jats:sup>18<\/jats:sup>F-fluciclovine and <jats:sup>68<\/jats:sup>Ga-PSMA-11 in patients with biochemical recurrence of PCa.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>58 patients with biochemical recurrence of PCa after definitive primary therapy were included. Both scans were performed within a time window of mean 9.4 days. All scans were visually analyzed independently on a patient-, region- and lesion-based analysis. All the examinations were performed in the same medical department using identical scanners at any time.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The overall detection rate for PCa recurrence was 79.3% in <jats:sup>18<\/jats:sup>F-fluciclovine and 82.8% in <jats:sup>68<\/jats:sup>Ga-PSMA-11 (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.64). Local recurrence was detected in 37.9% on <jats:sup>18<\/jats:sup>F-fluciclovine and in 27.6% on <jats:sup>68<\/jats:sup>Ga-PSMA-11 (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.03). Local pelvic lymph node recurrence was detected on <jats:sup>18<\/jats:sup>F-fluciclovine versus <jats:sup>68<\/jats:sup>Ga-PSMA-11 in 46.6% versus 50%, in extrapelvic lymph node metastases in 41.4% versus 51.7% and in bone metastases in 25.9% versus 36.2%. Lesion-based analysis showed identical findings in local pelvic lymph nodes in 39.7%, in extrapelvic lymph nodes in 22.4%, and in bone metastases in 13.8%.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The advantage of <jats:sup>18<\/jats:sup>F-fluciclovine is detecting curable localized disease in close anatomical relation to the urinary bladder, whereas <jats:sup>68<\/jats:sup>Ga-PSMA-11 fails because of accumulation of activity in the urinary bladder. <jats:sup>18<\/jats:sup>F-fluciclovine is almost equivalent to <jats:sup>68<\/jats:sup>Ga-PSMA-11 in detecting distant metastases of PCa recurrence.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000002703","type":"journal-article","created":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T15:55:12Z","timestamp":1562601312000},"page":"e566-e573","source":"Crossref","is-referenced-by-count":96,"title":["A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET\/CT"],"prefix":"10.1097","volume":"44","author":[{"given":"Birgit","family":"Pernthaler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Kulnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gstettner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spela","family":"Salamon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reingard M.","family":"Aigner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Kvaternik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,7,8]]},"reference":[{"key":"bib1-20230925","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"bib2-20230925","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1097\/RLU.0000000000002130","article-title":"Diagnostic performance of 18F-fluciclovine in detection of prostate cancer bone metastases","volume":"43","year":"2018","journal-title":"Clin Nucl Med"},{"key":"bib3-20230925","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1200\/JCO.2005.04.0756","article-title":"Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition","volume":"24","year":"2006","journal-title":"J Clin Oncol"},{"key":"bib4-20230925","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1016\/j.jacr.2018.03.019","article-title":"ACR Appropriateness Criteria\u00ae post-treatment follow-up prostate cancer","volume":"15","year":"2018","journal-title":"J Am Coll Radiol"},{"key":"bib5-20230925","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0090-4295(99)80421-X","article-title":"Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins","volume":"47","year":"1996","journal-title":"Urology"},{"key":"bib6-20230925","doi-asserted-by":"crossref","first-page":"e787","DOI":"10.1016\/j.ijrobp.2011.11.030","article-title":"Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study","volume":"82","year":"2012","journal-title":"Int J Radiat Oncol"},{"key":"bib7-20230925","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.prro.2017.07.011","article-title":"Prostate cancer\u2013specific PET radiotracers: a review on the clinical utility in recurrent disease","volume":"8","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"bib8-20230925","first-page":"20N","article-title":"SNMMI Leadership Update: FDA approval of imaging agents: an exciting investment in nuclear medicine","volume":"58","year":"2017","journal-title":"J Nucl Med"},{"key":"bib10-20230925","doi-asserted-by":"crossref","first-page":"61S","DOI":"10.2967\/jnumed.115.170209","article-title":"Evaluation of prostate cancer with radiolabeled amino acid analogs","volume":"57","year":"2016","journal-title":"J Nucl Med"},{"key":"bib11-20230925","first-page":"909","article-title":"Update on 18F-fluciclovine PET for prostate cancer imaging","volume":"43","year":"2018","journal-title":"J Nucl Med"},{"key":"bib12-20230925","first-page":"46","article-title":"A preliminary study of anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer","volume":"48","year":"2007","journal-title":"J Nucl Med"},{"key":"bib13-20230925","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.semcancer.2005.04.005","article-title":"Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime?","volume":"15","year":"2005","journal-title":"Semin Cancer Biol"},{"key":"bib14-20230925","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.nucmedbio.2015.07.005","article-title":"[14C]Fluciclovine (alias anti-[14C]FACBC) uptake and ASCT2 expression in castration-resistant prostate cancer cells","volume":"42","year":"2015","journal-title":"Nucl Med Biol"},{"key":"bib15-20230925","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","year":"1997","journal-title":"Clin Cancer Res"},{"key":"bib16-20230925","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2967\/jnumed.117.191031","article-title":"PSMA ligands for PET imaging of prostate cancer","volume":"58","year":"2017","journal-title":"J Nucl Med"},{"key":"bib17-20230925","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00259-013-2525-5","article-title":"Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET\/CT for the diagnosis of recurrent prostate cancer","volume":"41","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib18-20230925","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2967\/jnumed.115.161299","article-title":"The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET\/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions","volume":"56","year":"2015","journal-title":"J Nucl Med"},{"key":"bib19-20230925","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1590\/s1677-5538.ibju.2016.0656","article-title":"Biochemical recurrence after radical prostatectomy: what does it mean?","volume":"44","year":"2018","journal-title":"Int Braz J Urol"},{"key":"bib20-20230925","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","year":"2006","journal-title":"Int J Radiat Oncol"},{"key":"bib21-20230925","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3390\/ph7070779","article-title":"Novel preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer","volume":"7","year":"2014","journal-title":"Pharmaceuticals"},{"key":"bib22-20230925","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.2967\/jnumed.116.188375","article-title":"Reader training for the restaging of biochemically recurrent prostate cancer using 18F-fluciclovine PET\/CT","volume":"58","year":"2017","journal-title":"J Nucl Med"},{"key":"bib23-20230925","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1007\/s00259-017-3670-z","article-title":"68Ga-PSMA PET\/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib24-20230925","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.juro.2016.09.117","article-title":"Multisite experience of the safety, detection rate and diagnostic performance of fluciclovine (18F) positron emission tomography\/computerized tomography imaging in the staging of biochemically recurrent prostate cancer","volume":"197","year":"2017","journal-title":"J Urol"},{"key":"bib25-20230925","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s00259-016-3594-z","article-title":"Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET\/CT and PET\/MRI: comparison with mpMRI integrated in simultaneous PET\/MRI","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib26-20230925","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s00259-012-2291-9","article-title":"Regional distribution and kinetics of [18F]fluciclovine (anti-[18F]FACBC), a tracer of amino acid transport, in subjects with primary prostate cancer","volume":"40","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib27-20230925","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2967\/jnumed.117.203257","article-title":"Comparison of (68)Ga-PSMA-11 and (18)F-fluciclovine PET\/CT in a case series of 10 patients with prostate cancer recurrence","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib28-20230925","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3389\/fonc.2019.00071","article-title":"Stereotactic re-irradiation for local recurrence in the prostatic bed after prostatectomy: preliminary results","volume":"9","year":"2019","journal-title":"Front Oncol"},{"key":"bib29-20230925","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.ijrobp.2010.11.031","article-title":"Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer","volume":"82","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib30-20230925","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1007\/s00259-019-4258-6","article-title":"68Ga-PSMA PET\/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer","volume":"46","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib31-20230925","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/RLU.0000000000001240","article-title":"Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer","volume":"41","year":"2016","journal-title":"Clin Nucl Med"},{"key":"bib32-20230925","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/RLU.0000000000002212","article-title":"Long-term survival and excellent response to repeated 177Lu-prostate-specific membrane antigen 617 radioligand therapy in a patient with advanced metastatic castration-resistant prostate cancer","volume":"43","year":"2018","journal-title":"Clin Nucl Med"},{"key":"bib33-20230925","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.bbcan.2019.01.001","article-title":"Prostate cancer-specific hallmarks of amino acids metabolism: towards a paradigm of precision medicine","volume":"1871","year":"2019","journal-title":"Biochim Biophys Acta Rev Cancer"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000002703","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T06:01:21Z","timestamp":1695621681000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000002703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,8]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000002703","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7,8]]}}}